Stay Connected with ERT:
-
Recent Posts
- Improving Your Drug’s Value Proposition throughout the Product Lifecycle: How Optimized Clinical Outcomes Assessment (COA) Strategies Can Drive Commercialization Success
- Metrics Champion Consortium – Cardiopulmonary Performance Metrics Initiative
- The Importance of Inspiratory Capacity in COPD Clinical Trials
- CLEAR Study Update: A look inside the collaboration between ERT and UCLA
- Brief Report – Changes to the FDA Draft Guidance Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials
Archives
Monthly Archives: April 2012
Cardiac Safety in Obesity Drugs – FDA Advisory Committee
Written by: Dr. Robert Kleiman, Chief Medical Officer & Vice President, Global Cardiology Obesity is one of the nation’s largest health problems and has grown into a major epidemic. Over the past 20 years, obesity rates in the US have continued … Continue reading
